Comparative Pharmacology
Head-to-head clinical analysis: CLOBAZAM versus LIBERVANT.
Head-to-head clinical analysis: CLOBAZAM versus LIBERVANT.
CLOBAZAM vs LIBERVANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
None Documented
None Documented
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClobazam + Erythromycin
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Erythromycin can be decreased when combined with Clobazam."